Epstein - Barr virus Infection Treatment Market: Introduction
- Epstein - Barr virus (EBV) is a member of the herpes virus family, also known as human herpesvirus 4. It is a highly common human virus that spreads through body fluids, primarily saliva. Moreover, it can also spread through blood transfusions, organ transplantations, etc. This infection is generally contracted during childhood.
Key Drivers, Restrains and Opportunities of Global Epstein - Barr virus Infection Treatment Market
- Growing prevalence of Epstein-Barr virus infection is anticipated to drive the market. For instance, according to an article published in Frontiers in Oncology, Epstein-Barr virus is highly prevalent and it affects more than 90% individuals globally. Moreover, EBV seroprevalence increased with age and hence, a surge in the geriatric population is likely to fuel the market.
- Increase in awareness about novel therapeutics leads to a rise in the demand for Epstein - Barr virus infection treatment products. Thus, key players in the market are engaged in the development of new products to address unmet medical needs and subsequently, drive the market. For instance, LTCR-N1-1 is in the preclinical stage for the treatment of EBV-related nasopharyngeal carcinoma, conducted by LION TCR.
- However, a lack of specific findings in the early phase are is key factor that is likely to hamper the market
- Strong pipeline offers significant opportunity in the market. For instance, Baylor College of Medicine and collaborators The Methodist Hospital System conduct clinical trial for intravenous injection of EBV specific CTLS for Epstein-Barr virus infections
- Rise in government initiatives in developing countries to improve healthcare infrastructure is likely to create significant opportunity
North America to Capture Major Share of Global Epstein - Barr virus Infection Treatment Market
- North America is expected to account for a major share of the global Epstein - Barr virus infection treatment market due to high prevalence of the disease in the region. For instance, 95% adults in the U.S. affects by EBV infection are between the age of 35 and 40 years. Moreover, high diagnosis rate and large number of research & development activities conducted by key players are likely to augment the market. For instance, researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr virus (EBV). The study shows potential for treatment of Epstein - Barr virus-associated cancers.
- The Epstein - Barr virus infection treatment market treatment market in Asia Pacific is projected to expand at a rapid pace during the forecast period owing to improvement of healthcare infrastructure and rise in disposable income in the region. Moreover, improvement in adoption of novel therapeutics is likely to further augment the market.
Key Players Operating in Global Epstein - Barr virus Infection Treatment Market
The global Epstein - Barr virus infection treatment market is highly concentrated due to the presence of key players. A large number of manufacturers hold a major share in their respective regions. Demand for Epstein-Barr virus infection treatment products has increased in emerging as well as developed markets owing to a rise in prevalence of infection. Growth strategies adopted by leading players are likely to drive the global market.
Major players operating in the global Epstein-Barr virus infection treatment market are:
- Atara Biotherapeutics, Inc
- Bristol-Myers Squibb Company
- Lion TCR
- Vironika, LLC
Global Epstein - Barr Virus Infection Market: Research Scope
Global Epstein - Barr Virus Infection Market, by Drug
- Nucleoside analog
- Ganciclovir
- Valganciclovir
- Acyclovir
- Others
- Acyclic nucleotide analog
- Cidofovir
- Adefovir
- Others
- Pyrophosphate analog
- Others
Global Epstein - Barr Virus Infection Market, by Route of Administration
Global Epstein - Barr Virus Infection Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
*86 figures and 60 tables includes